摘要
癌症仍然是有效治疗的致命疾病。虽然异常肿瘤微环境现在被广泛用于靶向化学疗法,但仍然不能安全有效地向肿瘤细胞递送药物。脂质体是有前途的可生物降解和生物相容的纳米载体,具有表面和内部修饰的潜在适应性,以及携带亲水性和疏水性药物的非凡能力。用肿瘤选择性配体和聚乙二醇化精心制造脂质体降低了免疫原性并增加了靶特异性。这篇综述着重于脂质体的关键发育方面,以利用增强的渗透性和保留(EPR)效应以及肿瘤选择性配体(如叶酸,转铁蛋白,多肽等)靶向癌细胞。此外,刺激响应智能脂质体(触发因素:pH,温度,还研究了酶,磁场,超声波和氧化还原电位等,以增强向肿瘤的药物递送。该综述总结了通过各种靶向手段靶向肿瘤的脂质体的进展。这种知识丰富的脂质体方法进展将为配方设计师和崭露头角的科学家提供新的见解,以设计针对癌症的脂质体。
关键词: 癌症,化疗,主动靶向,配体,抗癌剂,EPR效应,PEG化。
Current Molecular Medicine
Title:Advances in Tumor Targeted Liposomes
Volume: 18 Issue: 1
关键词: 癌症,化疗,主动靶向,配体,抗癌剂,EPR效应,PEG化。
摘要: Cancer remains a deadly disease for effective treatment. Although anomalous tumor microenvironment is now widely exploited for targeted chemotherapy, safe and efficacious drug delivery to tumor cells is not still warranted. Liposomes are promising biodegradable and biocompatible nanocarriers having potential amenability for surface and internal modifications, and extraordinary capability to carry both hydrophilic as well as hydrophobhic drugs. Meticulous fabrication of liposomes with tumor selective ligand(s) and PEGylation reduces immunogenicity and increase target-specificity. This review focuses on critical developmental aspects of liposomes to target cancer cells exploiting Enhanced Permeability and Retention (EPR) effect and tumor-selective ligands such as folate, transferrin, peptides etc. Moreover, stimuli-responsive smart liposomes (triggers: pH, temperature, enzymes, magnetic field, ultrasound, and redox potential etc.) are also investigated for enhancement of drug delivery to tumors. This review summarizes advances in tumor-targeted liposomes via various means of targeting. This knowledgeable assemblage of advances in liposomal approaches will render new insights to formulators and budding scientists to design cancer targeted liposomes.
Export Options
About this article
Cite this article as:
Advances in Tumor Targeted Liposomes, Current Molecular Medicine 2018; 18 (1) . https://dx.doi.org/10.2174/1566524018666180416101522
DOI https://dx.doi.org/10.2174/1566524018666180416101522 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Limiting Functional Deficiency Following Stroke: Exploiting Different Stem Cell Reservoirs
Current Neuropharmacology Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design The Expanding Role of Tumor Necrosis Factor-α Inhibitors in the Management of Rheumatic Diseases
Medicinal Chemistry Reviews - Online (Discontinued) Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine Immunity to Tumour Antigens
Current Pharmaceutical Design Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Drugs, Environmental Factors, Loci and Genes Involved in Nonsyndromic Orofacial Cleft
Current Pharmacogenomics Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry